

Paper No. \_\_\_\_  
Date Filed: May 18, 2015

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

LUPIN LIMITED  
Petitioner

v.

JANSSEN SCIENCES IRELAND UC  
Patent Owner

---

Case IPR2015-01030  
Patent 8,518,987 B2

---

**JANSSEN SCIENCES IRELAND UC'S  
UPDATED MANDATORY NOTICES**

Pursuant to 37 C.F.R. §42.8, Janssen Sciences Ireland UC (“Janssen”) submits the following mandatory notices to update the status of related district court actions disclosed in Janssen’s original mandatory notices (*see* Paper 6) that have now been terminated.

### **REAL PARTY-IN-INTEREST**

Janssen, an indirect, wholly-owned subsidiary of Johnson & Johnson (“J&J”), is a real party-in-interest. Janssen Products, L.P., a wholly-owned subsidiary of J&J is also a real party-in-interest. In addition, J&J, a publicly held company, is a real party-in-interest.

### **RELATED MATTERS**

U.S. Patent 8,518,987 (the “’987 Patent”) issued from U.S. Application No. 12/536,807 (the “’807 Application”). U.S. Patent Application No. 14/183,712, which is currently pending before the Office, is a continuation of U.S. Application 13/939,494 (now abandoned), which is itself a continuation of the ’807 Application.

The ’987 Patent is being asserted in the following patent infringement lawsuit:

- *Janssen Prods., L.P. et al. v. Lupin Ltd. et al.*, C.A. No. 13-3891 (D.N.J.).

The '987 Patent was at issue in the following lawsuits that have now been terminated:

- *Janssen Prods., L.P. et al. v. Teva Pharm. USA, Inc. et al.*, C.A. No. 13-7576 (D.N.J.) (terminated due to consent judgment of enforceability, validity and infringement of the '987 patent with respect to Teva ANDA product);
- *Janssen Prods., L.P. et al. v. Cipla Ltd. et al.*, C.A. No. 15-0307 (D. Del.) (terminated due to consent judgment of enforceability, validity and infringement of the '987 patent with respect to Cipla ANDA product);
- *Janssen Prods., L.P. et al. v. Cipla Ltd. et al.*, C.A. No. 14-1056 (D. Del.) (terminated due to consent judgment of enforceability, validity and infringement of the '987 patent with respect to Cipla ANDA product);
- *Janssen Prods., L.P. et al. v. Cipla Ltd. et al.*, C.A. No. 15-2549 (D.N.J.) (dismissed by stipulation of the parties in light of consent judgment entered in the District of Delaware, C.A. No. 15-0307);

- *Janssen Prods., L.P. et al. v. Cipla Ltd. et al.*, C.A. No. 14-5093 (D.N.J.) (dismissed by stipulation of the parties in light of consent judgment entered in the District of Delaware, C.A. No. 14-1056); and
- *Janssen Prods., L.P. et al. v. Lupin Ltd. et al.*, C.A. No. 14-1370 (D.N.J.) (terminated due to consolidation with C.A. No. 13-3891).

The '807 Application is a divisional of U.S. Application No. 10/514,352, which issued as U.S. Patent No. 7,700,645 (the "'645 Patent"). The '645 Patent is the subject of the following lawsuits:

- *Janssen Prods., L.P. et al. v. Lupin Ltd. et al.*, C.A. No. 10-5954 (D.N.J.) (pending Consolidated Appeal No. 14-1842 (Fed. Cir.)); and
- *Janssen Prods., L.P. et al. v. Lupin Ltd. et al.*, C.A. No. 13-3891 (D.N.J.) (also listed above with respect to the '987 Patent).

The '645 Patent was at issue in the following lawsuits that have now been terminated:

- *Tibotec Inc. et al. v. Teva Pharm. USA, Inc. et al.*, C.A. No. 11-1509 (D.N.J.) (consolidated with C.A. No. 10-5954 and dismissed due to consent judgment of enforceability, validity and infringement of the '645 patent with respect to Teva ANDA product);
- *Tibotec Inc. et al. v. Lupin Ltd. et al.*, C.A. No. 11-4027 (D.N.J.) (terminated due to consolidation with C.A. No. 10-5954);

- *Janssen Prods., L.P. et al. v. Cipla Ltd. et al.*, C.A. No. 15-0307 (D. Del.) (also listed above with respect to the '987 Patent and now dismissed due to consent judgment of enforceability, validity and infringement of the '645 patent with respect to Cipla ANDA product);
- *Janssen Prods., L.P. et al. v. Cipla Ltd. et al.*, C.A. No. 14-1056 (D. Del.) (also listed above with respect to the '987 Patent and now dismissed due to consent judgment of enforceability, validity and infringement of the '645 patent with respect to Cipla ANDA product);
- *Janssen Prods., L.P. et al. v. Cipla Ltd. et al.*, C.A. No. 15-2549 (D.N.J.) (also listed above with respect to the '987 Patent and now dismissed by stipulation of the parties in light of consent judgment entered in the District of Delaware, C.A. No. 15-cv-0307); and
- *Janssen Prods., L.P. et al. v. Cipla Ltd. et al.*, C.A. No. 14-5093 (D.N.J.) (also listed above with respect to the '987 Patent and now dismissed by stipulation of the parties in light of consent judgment entered in the District of Delaware, C.A. No. 14-cv-01056).

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.